Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential
1. MAZE reports Phase 1 results for MZE782 targeting key health disorders. 2. MZE782 shows significant increases in amino acid excretion, confirming efficacy. 3. MZE782 well tolerated; no serious adverse events reported during trials. 4. Company plans Phase 2 trials for MZE782 efficacy in PKU and CKD. 5. MAZE shares up over 52% and reach new 52-week high.